{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016852","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.040437+00:00","generated_at":"2026-06-09T08:38:26.132744+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA accepts IND for Mustang Bio's MB-109 combo therapy for recurrent glioblastoma","bullets":["IND accepted within 30 days of submission for MB-109 (MB-101 CAR-T + MB-108 oncolytic virus).","Phase 1 trial to start 2024; will test safety, tolerability, efficacy in recurrent GBM and high-grade astrocytoma.","Prior MB-101 alone saw complete responses lasting 7.5 and 31+ months in patients with hot tumors.","Study to enroll at City of Hope and University of Alabama at Birmingham.","Median overall survival for recurrent GBM is 6 months; combo aims to improve outcomes."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016852","json":"https://secwatch.observer/filing/0001558370-23-016852.json","markdown":"https://secwatch.observer/filing/0001558370-23-016852.md","text":"https://secwatch.observer/filing/0001558370-23-016852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023016852/0001558370-23-016852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023016852/tmb-20231026x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:38:26.132744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}